Cimon Medical develops the NeoDoppler system, a novel Doppler ultrasound technology that provides continuous, non-invasive monitoring of cerebral blood flow. This technology addresses the lack of direct measurement options for brain blood flow, particularly in vulnerable populations such as newborns during transport.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Continuous, direct measurement of cerebral blood flow is lacking, particularly in vulnerable populations like newborns during transport, hindering timely intervention and potentially impacting outcomes. Current monitoring methods are often indirect or invasive, posing risks and limitations in dynamic clinical settings.
Solution
Cimon Medical's NeoDoppler system offers a non-invasive solution for continuous cerebral blood flow monitoring using Doppler ultrasound technology. The system provides real-time data on cerebral perfusion, enabling clinicians to make informed decisions, especially during critical transport situations. NeoDoppler addresses the challenges of monitoring newborns by offering a well-tolerated and easy-to-use device. The technology aims to improve the assessment of cerebral perfusion, offering a promising advancement in neonatal care.
Target Audience
The primary target audience includes healthcare facilities, neonatologists, and transport teams involved in the care of newborns, particularly those requiring continuous monitoring of cerebral blood flow.
Features
- Continuous, non-invasive monitoring of cerebral blood flow
- Doppler ultrasound technology for real-time data acquisition
- Designed for use during incubator transport of newborns
- CE certified for distribution and sales in Europe